Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04338659 · ClinicalTrials.gov registry record · Phase 1
A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers
A Phase 1 study, sponsored by Innovent Biologics (Suzhou) Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT04338659 is a Phase 1 study that has completed, run by Innovent Biologics (Suzhou) Co.. The registered enrollment target is 22 participants.
The verdict
NCT04338659, a Phase 1 study, has completed, sponsored by Innovent Biologics (Suzhou) Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This is a phase I study evaluating the safety, tolerability and preliminary efficacy of IBI322 in cancer subjects who failed standard treatment.
Interventions
- BIOLOGICAL IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2021-01-14 |
| Est. Completion | 2023-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04338659
The ClinicalTrials.gov registry entry for NCT04338659 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Innovent Biologics (Suzhou) Co., which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection is the first listed.
NCT04338659 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04338659 about?
NCT04338659 is a clinical study titled "A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers". This is a phase I study evaluating the safety, tolerability and preliminary efficacy of IBI322 in cancer subjects who failed standard treatment.
What is the current status of trial NCT04338659?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2021-01-14. Estimated completion is 2023-02-28.
What interventions are being tested in trial NCT04338659?
The interventions under investigation include: IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection (BIOLOGICAL).
Who is sponsoring clinical trial NCT04338659?
This trial is sponsored by Innovent Biologics (Suzhou) Co., which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.